CureVac N.V. (CVAC)
NASDAQ: CVAC · Real-Time Price · USD
5.50
+0.03 (0.55%)
At close: Aug 13, 2025, 4:00 PM
5.45
-0.05 (-0.91%)
Pre-market: Aug 14, 2025, 9:04 AM EDT
CureVac Employees
As of December 31, 2024, CureVac had 983 total employees, including 825 full-time and 158 part-time employees. The number of employees decreased by 189 or -16.13% compared to the previous year.
Employees
983
Change (1Y)
-189
Growth (1Y)
-16.13%
Revenue / Employee
$575,829
Profits / Employee
$198,637
Market Cap
1.24B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CVAC News
- 6 days ago - CureVac settles patent dispute litigation with Pfizer and BioNTech - Reuters
- 7 weeks ago - CureVac Announces Voting Results of General Meeting - Accesswire
- 2 months ago - Top Stock Movers Now: Oracle, Boeing, CureVac, and More - Investopedia
- 2 months ago - BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal - Benzinga
- 2 months ago - BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising. - Barrons
- 2 months ago - BioNTech to acquire CureVac in $1.25 billion all-stock deal - Reuters
- 3 months ago - CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates - Accesswire
- 3 months ago - CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE - Accesswire